RATP Group subsidiary RATP Dev has concluded a comprehensive study to implement the 360 Mobility Plan for the Royal Commission for AlUla (RCU), marking a step in the development of “sustainable ...

Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for RAPT Therapeutics in a note issued to investors ...

“Our focus for 2025 will be on advancing development of RPT904, a novel, potentia Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected ...

Research and development expenses for the fourth quarter ... equivalents and marketable securities of $231.1 million. About RAPT Therapeutics, Inc. RAPT Therapeutics, Inc. (“RAPT” or the ...

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering ...

“Our focus for 2025 will be on advancing development of RPT904 ... President and CEO of RAPT. “We believe RPT904 can be a differentiated product to treat these diseases by targeting IgE ...

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies ...